Breo Ellipta (GlaxoSmithKline/Innoviva) Drug Analysis 2018

Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disorder.

Fluticasone furoate is an inhaled corticosteroid that activates the glucocorticoid response element and inhibits pro-inflammatory transcription factors such as NF?B, and antigen-induced lung eosinophilia, thereby suppressing inflammation.

Vilanterol is a long-acting beta 2 agonist that stimulates intracellular adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate to cyclic-3',5'-adenosine monophosphate (AMP). Increased levels of cyclic AMP result in the relaxation of bronchial smooth muscles and inhibition of the release of mediators of immediate hypersensitivity from mast cells.

Key Topics Covered:

1 Product Profiles

• Breo: Chronic obstructive pulmonary disease (COPD)
• Breo Ellipta: Asthma

List of Figures

Figure 52: The author's drug assessment summary of Xolair in asthma

Figure 53: The author's drug assessment summary of Xolair in asthma

Figure 54: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 4: Breo Ellipta for asthma - SWOT analysis

Figure 5: The author's drug assessment summary of Breo Ellipta in asthma

Figure 6: The author's drug assessment summary of Breo Ellipta in asthma

Figure 7: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Breo drug profile

Table 2: Phase III trial data for Breo in COPD

Table 3: Breo late-phase trial data in COPD

Table 4: Breo Ellipta drug profile

Table 5: Breo Ellipta pivotal trial data in asthma

Table 6: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 7: Breo Ellipta sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Register as Visitor to CPhI China 2018!